{
  "docId": "019de075-6448-707d-82ec-cbbeebb7feb3",
  "docSlug": "1eef6abd03697885c8a70f789c554a37",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 23,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-6448-707d-82ec-cbbeebb7feb3/3",
  "deckHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3",
  "deckJsonHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3.json",
  "deckAnchorHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.76
      },
      "kind": "list",
      "text": "Management Team with Strong Track Record: 3 approved drugs in 4 indications in the US and EU and multiple strategic deals; Cash runway into 1H2025; Stock added to the Russell 2000 index in June 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fe9b306-f03d-4f84-ae67-07b2e0b94220",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.585
      },
      "kind": "list",
      "text": "NXP900 – IND accepted: Phase 1a expected to begin 3Q2023; First potential indications: YES1/SRC-driven solid tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29a52d0c-9a8c-4536-add1-53bd5c817c30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.235
      },
      "kind": "list",
      "text": "Our Approach to Precision Medicine: Select and acquire novel, rationally-designed drug candidates; Focus on drug development for serious conditions of unmet need in oncology",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f7a0b31-08a0-4242-9698-d65868dd4367",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.41
      },
      "kind": "list",
      "text": "NXP800 – Phase 1b: Fast Track Designation for platinum-resistant, ARID1a-mutated ovarian carcinoma; Phase 1b study initiated in collaboration with ENGOT/GOG",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd8b26b4-0014-45b6-936d-f27848edbabf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Nuvectis Pharma – Key Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7966a058-c813-402e-baf5-af3fc63b12f9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "7738cccc-e2c0-488d-97a8-80421367ad0a",
      "evidence": "This slide provides a summary of key highlights.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 3,
      "beatId": "e11c5988-f13d-4b29-8d02-9ad9e8992abc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The deck presents an overview of Nuvectis Pharma's pipeline and the challenges they aim to address.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}